Integrated metabolic flux and omics analysis of leishmania major metabolism by Shakyawar, S. et al.
 
 










SilicoLife Lda, Braga, Portugal 
2
University of Minho, Braga, Portugal 
*Corresponding author: scarneiro@silicolife.com
Abstract 
Leishmaniasis is a virulent parasitic infection that causes a 
significant threat to human health worldwide. The existing 
drugs are becoming less effective due to the ability of 
Leishmania spp. to alter its metabolism to adapt to harsh 
environments. Understanding how this parasite manipulates its 
metabolism inside the host (e.g. sandfly and human) might 
underpin new ways to prevent the disease and develop 
effective treatment strategies. 
Despite significant advances in omics technologies, 
biochemistry of parasites still lacks the understanding of 
molecular components that determine the metabolic behavior 
under varying conditions. Metabolic network modeling might 
be of interest to identify physiologically relevant nodes in a 
metabolic network.  
The present work proposes a metabolic model iSK570 (an 
extension of the iAC560 model) with additional reactions for 
the metabolism of lipids, long chain fatty acids and 
carbohydrates to study the metabolic behavior of this parasite. 
Gene Inactivity Moderated by Metabolism and Expression 
(GIMME) algorithm was used to verify the consistency 
between model flux predictions and gene expression data. 
Improved flux distributions were obtained, allowing a more 
accurate understanding of stage-specific metabolism in of 
promastigotes and amastigotes.  
1. Introduction 
Protozoan parasites from the genus Leishmania belong to the 
family Trypanosomatidae, and cause a spectrum of human 
diseases affecting around 12 million people worldwide 
(www.who.int). Existing treatment therapies involving drugs 
such as e.g. sodium stibogluconate and meglumine 
antimoniate, amphotericin B and miltefosine are limited by 
various features, including in some cases host toxicity and 
lack of efficacy [1,2]. Considering endemic severity of the 
disease, there is an urgent need for understanding Leishmania 
metabolism which can subsequently help in developing novel 
anti-leishmanial therapies.  
Significant alterations have been observed in the metabolism 
exhibited by Leishmania at different stages of its life cycle, 
where it faces different nutritional environments [3]. For 
example, the promastigote form (inside sandfly) of 
Leishmania preferably uses glucose and L-proline via 
glycolysis pathways and TCA cycle; while amastigote uses 
glucosamine (GlcN) and its derivative N-acetylglucosamine 
(GlcNAc)along with some lipids and amino acids [4,5]. 
Availability of various sugars, such as hexoses (e.g. glucose, 
mannose, and galactose) and amino sugars (e.g. GlcN and 
GlcNAc) are determining factors for parasitic metabolic 
phenotype, especially for synthesizing essential glycans and 
glycoconjugates [6].  
Unfortunately, no previous studies have explained the 
metabolic basis leading to the biosynthesis of glycans and 
glycoconjugates in the presence of different environments. In 
fact, it is still unknown if observed metabolic changes are 
resulting from, or arising out of the different parasitic stages. 
For example, under promastigote stage, only a few enzymes 
from the TCA cycle are active, while in amastigote stage, 
glycolytic enzymes are less functional. 
Metabolic network modeling is an effective and sophisticated 
approach for systematically study the metabolic behaviour of 
an organism, as well as to understand the relationship between 
its genotype and phenotype. Previously, these methods have 
been used to understand the cellular metabolism as well as to 
identify essential genes in many medically important 
organisms, such as Mycobacterium tuberculosis [7], 
Acinetobacter baumanii [8], Francisella tularensis [9] 
including human parasites like Leishmania major [10] and 
Plasmodium falciparum [11]; though with the low prediction 
accuracy. One of the most probable and obvious reasons for 
the low prediction accuracy might be associated with the lack 
of use of experimental data (e.g. transcriptomics, proteomics, 
and metabolomics etc.) to constrain the model and 
unavailability of the suitable strategies to use omics data in the 
metabolic network analyses.  
Integrating omics data with metabolic network analysis can 
improve our understanding on various aspects, such as 
metabolic alterations associated with the environmental 
conditions, essential genes and metabolic flux variability of 
the essential reactions [12]. The relevant data can be 
integrated into the metabolic model to provide an extra layer 
of metabolic flux constraints to improve its overall prediction 
efficiency. Various methods like GIMME [13], iMAT [14], 
MADE [15], E-Flux [15] and PROM [16] have been made 
available for the integration of transcriptomics and genomics, 
fluxomics [17], and metabolomics [18] data into metabolic 
models. Successful examples include the integration of 
RNAseq data into the Leishmania infantum model [19],  
proteomics data into a metabolic model of Enterococcus 
faecalis [20], and multi-omics data into metabolic models of 
Escherichia coli [21] to understand the metabolism and 
associated phenotypes. The strategy has also improved drug 
target predictions in many medically important organisms 
such as Aspergillus fumigatus [22], Plasmodium falciparum 
[23] and L. major [24]. 
In spite of the availability of abundant omics data and various 
methodologies, only a few studies have employed these 
strategies to understand the metabolism of Leishmania 
[10,19,25]. Here, we applied omics data with metabolic 
modeling approaches to understand the metabolic profile of L. 
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major under different environmental conditions. The 
workflow mainly includes the integration of gene expression 
data from promastigote and amastigote stages into our 
metabolic model using Gene Inactivity Moderated by 
Metabolism and Expression (GIMME) method [13].  
2. Methodology 
2.1. Model extension and refinement  
The existing metabolic model iAC560 [10] was extended to 
include sugar nucleotides biosynthetic pathways, which 
reactions and enzyme-coding genes were collected from 
databases like KEGG [26] and LeishCyc [27]. As some of the 
reaction steps were not associated with a specific gene, 
homology search tools like BLAST [1], were applied to find 
the highest scoring gene sequences (% identity ≥ 40%, 
alignment length ≥ 70% and E-value 1.0e-30), as described in 
[19] and associate those to the corresponding reactions. 
Additionally, based on experimental evidence, several 
metabolic reactions were altered in terms of reversibility 
and/or compartments, while new transport reactions for sugar 
nucleotides, lipids, and fatty acids were also included. Refer to 
Supplementary material S1 for added, deleted or altered 
reactions. 
 
2.2. Biomass composition 
 
The macromolecular composition of L. major cells was also 
corrected. Protein, DNA and RNA contents were estimated 
from L. donovani studies [19], while carbohydrates, lipids, and 
polyamine contents were calculated using experimental data 
from protozoan Tetrahymena [28,29] and L. mexicana [30]. 
Individual carbohydrates, such as mannan, lipophosphoglycan 
(LPG), glycoinositol phospholipid (GIPL), and N-glycans, 
were estimated as follows: mannan contents were assumed to 
represent 80% and 90 % of all carbohydrates in promastigote 
and amastigote stage, respectively [30], while LPG, GIPL, and 
N-glycans would represent 20% and 10% in total, 
respectively. The relative mass fractions (w/w) of LPG, GIPL, 
and N-glycans were estimated based on previous studies [31–
34]. Further details on biomass calculations can be found in 
Supplementary material S2. 
 
2.3. In-silico media formulation 
2.3.1. Modified Media for Promastigote (MMP)  
MMP was formulated for L. major growth under promastigote 
stage, which includes 16 nutrient sources: L-arginine, L-
cysteine, L-histidine, L-isoleucine, L-leucine, L-lysine, L-
methionine, L-phenylalanine, L-threonine, L-tyrosine, L-
valine, hypoxanthine, phosphate, oxygen, proline, and 
glucose. The nutrients, in particular, glucose and proline were 
considered based on the previous studies [35,36], explaining 
that both the compounds are major carbon source for 
Leishmania promastigote, while remaining ones were included 
considering the experimental studies [37,38] and 
computational predictions in [10], which concluded that 
Leishmania can grow in these nutrients. 
 
2.3.2. Modified Media for Amastigote (MMA)  
MMA includes all 16 nutrients from MMP with additional 
amino sugars, amino acids, lipids and fatty acids, making a 
total of 21 nutrients. GlcN and GlcNAc sugars were added 
considering findings from Naderer et al. (2010) studies [4] that 
showed the degradation of glycosaminoglycans inside 
macrophages to provide GlcN and GlcNAc as carbon sources 
during the amastigote stage. Fatty acids like stearyl acid and 
lipids, e.g. phosphatidylethanolamine were also considered, 
based on different studies that show that Leishmania utilizes 
lipids from host cells and transports them into the cytosol 
[39,40]. The consumption of the lipids and fatty acids during 
amastigote stages were also supported by other experimental 
studies discussing the possibility of growth of Leishmania 
axenic amastigote in lipid and fatty acid-rich medium [41–43]. 
The amino acids aspartate and alanine were also added to 
MMA, based on higher consumption measurements of these 
amino acids as carbon sources by amastigotes [44]. 
 
2.4. Reaction flux constraints in FBA-based 
simulations 
 
Model simulations under amastigote and promastigote stages 
were estimated using different reaction constraints. For 
example, the uptake flux for proline was reduced by 90% in 
amastigote compared to promastigote simulations, based on 
the previous study showing a decrease in the consumption of 
this particular amino acid in L. mexicana amastigotes [35]. 
Also, glucose uptake flux was constrained to 90% less than 
that in the promastigote stage, considering previous findings 
[45,46], which concluded that parasitophorous vacuole is a 
compartment poor in glucose. Furthermore, the oxygen uptake 
in amastigote stage was significantly reduced as compared to 
that in the promastigote stage, considering the fact that 
Leishmania-infected macrophage is an oxygen-deficient entity 
[47,48]. The upper and lower limits for uptake fluxes for all 
other nutrients were set unconstrained (See Supplementary 
material S2). 
 
2.5. Metabolic network analysis 
 
The gene expression data (FPKM
1
 values) of 10275 genes 
from Leishmania spp. [49] was integrated with the extended 
metabolic model (termed as iSK570) by applying GIMME 
approach. OptFlux modules [50] were used to run GIMME 
algorithm and to perform FBA-based analyses under different 
environmental conditions.  
Briefly, GIMME implementation considers genes (and 
associated reactions) with an expression level below the 
threshold as inactive, and thus removes those from the 
simulation. The algorithm may reconsider few of these 
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inactive reactions, especially the essential ones and so-called 
metabolically important reactions (MIRs), back in the 
simulation to achieve an optimal solution. The remaining 
reactions are blocked and termed as metabolically unwanted 
reactions (MURs) in that particular metabolic state. 
Inconsistencies between the metabolic model and gene 
expression data are estimated based on MIRs that are re-
inserted in the model; however, GIMME solves a linear 
programming (LP) on reconsidered reactions to minimize this 
inconsistency. As such, inconsistency scores (IS) are 
calculated and associated with each metabolic reaction. 




Figure 1: A) Workflow for integrating gene expression data 
into the metabolic. B) An exemplifying scheme for calculating 
inconsistency score (IS) using gene expression and flux 
values. 
 
(1) inactive (expression levels below the threshold and 
metabolic flux
2
 equal to zero); 
(2) potentially inactive (expression levels below the 
threshold and metabolic flux
2
 is non-zero);  
(3) potentially active (expression levels above the 
threshold and metabolic flux
2
 equal to zero); 
(4) active (expression levels above the threshold and 
metabolic flux
2
 is non-zero). 
Different threshold values were tested, and inconsistency 
scores (IS) were recalculated as described in [13] (Figure 1). 
Furthermore, flux spans
3
 based on Flux Variability Analysis 
(FVA) and PFBA flux distributions were compared. The 
predicted changes in metabolic operability of reactions after 
GIMME implementation were also compared with proteomic 
data from Pawar et al. (2014) [51]. 
 
3. Results and Discussion 
 
3.1. Consistency between metabolic model 
iSK570 and gene expression data in 
promastigote conditions 
 
Based on different tests, where the gene expression threshold 
values were changed, it was observed that IS values increase 
with the threshold values (Figure 2A), particularly above 
threshold values of 11 (Figure 2B). Below this threshold, IS 
values are close to zero, indicating that there are only a few 
inconsistencies between predicted fluxes and gene expression 
levels associated to the corresponding reactions. As such, 
while increasing the threshold value more reactions with 
predicted fluxes different from zero, but with low expression 
levels, i.e. reactions that should be active, are included, which 
increases the level of inconsistency between expression data 
and flux predictions. Although the number of potentially 
inactive reactions, i.e. reactions with expression levels below 
the threshold and predicted zero flux, increases with the 
threshold value, agreeing with metabolic predictions; the fact 
is that increasing the threshold value tends to exclude 
reactions that should be active as predicted by FBA-based 
simulations.  
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 Metabolic flux was calculated by performing GIMME which uses  
Parsimonious Flux Balance Analysis (PFBA) to run simulations. 
3
 Flux span refers to the difference between maximum and minimum flux 




Figure 2: Evaluating inconsistencies between iSK570 model 
predictions and gene expression data from L. major 
promastigote cells. A) Inconsistency scores (IS) were 
calculated for different expression threshold values, while 
estimating the number of reactions with gene expression levels 
below a threshold value and predicted flux values equal and 
different from zero. B) Zoom in of plot A for lower threshold 
values, showing the variation in the inconsistency score and 
the number of reactions with gene expression below threshold 
flux values different and equal to zero. 
As shown in Figure 2A, the number of potentially inactive 
reactions (i.e. with gene expression less than the threshold and 
predicted flux equal to zero) increases to a maximum of 400 at 
the highest expression threshold value (368). In general, 
GIMME considers these reactions as MURs (or metabolically 
unwanted reactions) and, ultimately they do not have an 
impact on the flux distribution. Similarly, potentially active 
reactions (i.e. with gene expression less than threshold and 
flux equal to zero) can be associated with MIRs and GIMME 
might need to reconsider some of these reactions during the 
simulation process. These are almost 250 at a maximum 
threshold value of 368. Although the number of MIRs are 
lower than the number of MURs at a particular threshold 
value, these contribute far more to increase IS values. 
Therefore a threshold value should be carefully selected. In 
the following analysis, a threshold value of 12 (equivalent IS = 
5.9×10
2
) was chosen to perform GIMME simulations, which 
predicted 30 genes (out of 570) with expression levels below 
the threshold value, corresponding to 23 reactions from which 
16 were considered MURs and 7 MIRs. 
 
3.2. FVA and PFBA analyses  
 
FVA analyses were performed based on GIMME results using 
a threshold value of 12. Briefly, the idea was to evaluate 
changes in metabolic predictions imposed by GIMME 
constraints (especially blocked reactions or MURs) and 
estimate the impact in the predicted metabolic flexibility under 
the defined conditions. Therefore, FVA analyses with and 
without GIMME constraints were compared. Reactions were 
categorized as such: type1, minimum and maximum FVA 
fluxes equal to zero; type2, minimum and maximum FVA 
fluxes different from zero (either positive or negative); and 
type3, minimum and maximum FVA fluxes equal to upper 
and lower bounds of reactions (Table 1). 
Results show that the number of reactions type3 decreased, 
while reactions type1 and type2 increased, which suggests that 
GIMME-based constraints reduced metabolic flexibility 
associated with large FVA spans as defined by FVA fluxes of 
type 3 reactions. Also, reactions type 1 with FVA spans of 
zero (i.e. blocked reactions) contribute to decrease this 
metabolic flexibility, as the number of possible alternatives for 
carbon distribution within the network also decreases. 
Minimum and maximum flux values from FVA analyses with 
and without GIMME constraints for each reaction are 
presented in Supplementary material S1. 
 
Table 1: Number of reactions classified as type1, type2 and 
type3 from FVA results considering simulations with and 
without GIMME-based constraints (i.e. deleting MURs).  
Reaction 
Category 
Minimum (min) and 
maximum (max) 
FVA values 
Number of reactions 








type1 min = 0 and 
max = 0 
472 493 
type2 min/max< 0  
or min/max > 0 
239 256 




Additionally, PFBA and GIMME flux distributions were 
compared. In general, flux distributions did not change 
significantly, most likely because of small differences in the 
number of active and non-active reactions (Figure 3A); 
however, few reactions changed their flux values from zero to 
non-zero and vice-versa. The reactions with these binary 
changes are mostly transport reactions, but reactions 
associated with metabolic pathways like “Glycerolipid 
metabolism” (30.3 %) and “Pyrimidine metabolism” (9.09%) 
(Figure 3B) were also found. Changes in flux operability of 
these reactions can be supported by proteomic data for L. 
major from Pawar et al., 2014 [51], which showed that genes 
associated with eight reactions (out of ten) that changed their 
fluxes from zero to non-zero, are expressed at the protein level 
(Table 2). This indicates that GIMME-based flux analyses 




Table 2: List of reactions which showed binary changes (zero 
to non-zero) in their fluxes after GIMME implementation 
(threshold value of 12), and which associated enzymes have 
positive expression at protein level. 
Reaction ID 
 












0 4.80 LmjF32.1960 yes 
R_CDPDSPm_
LM  
0 3.26 LmjF14.1200 yes 
R_GPAM_LM  0 4.80 LmjF34.1090 yes 






R_ME1x  0 162.49 LmjF24.0770 yes 




R_PNS1  0 10000 LmjF29.2800 yes 





Figure 3: A) Changes in the number of reactions with 
predicted flux = 0 or ≠ 0 after GIMME implementation. B) 
Percentage cellular distribution of the reactions which showed 
binary changes in their fluxes after GIMME. 
4. Conclusion 
 
The work described the application of GIMME algorithm in 
combination with flux-based analysis to integrate gene 
expression data into genome-scale models to determine 
consistency between data and metabolic model iSK570. The 
strategy has been used to put an extra layer of stoichiometric 
constraints on reactions to predict more accurate fluxes across 
various pathways of L. major. The predicted 
activation/inactivation of the metabolic reactions in a 
particular environment was supported by expression of the 
associated enzymes at the protein level. Improved flux 
distribution further used to describe stage-specific metabolism 
and drug target predictions in Leishmania (not described here 
due to page limitations). All supplementary data mentioned in 
this manuscript can be provided on demand. 
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